Fibroblast-Activated Protein Inhibitor PET/CT: Cancer Diagnosis and Management

Fibroblast activation protein (FAP), overexpressed on cancer-associated fibroblasts (CAFs), is a novel target for molecular imaging of various tumors. Recently, the development of several small-molecule FAP inhibitors for radiolabeling with 68Ga has resulted in the emergence of studies evaluating it...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Serkan Kuyumcu, Yasemin Sanli, Rathan M. Subramaniam
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	PET cancer-associated fibroblast fibroblast activation protein theranostic 68Ga-FAPI04 FAPI Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/f6b7392e8fb940db825892af269b3b9a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f6b7392e8fb940db825892af269b3b9a
record_format	dspace
spelling	oai:doaj.org-article:f6b7392e8fb940db825892af269b3b9a2021-11-11T08:17:49ZFibroblast-Activated Protein Inhibitor PET/CT: Cancer Diagnosis and Management2234-943X10.3389/fonc.2021.758958https://doaj.org/article/f6b7392e8fb940db825892af269b3b9a2021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fonc.2021.758958/fullhttps://doaj.org/toc/2234-943XFibroblast activation protein (FAP), overexpressed on cancer-associated fibroblasts (CAFs), is a novel target for molecular imaging of various tumors. Recently, the development of several small-molecule FAP inhibitors for radiolabeling with 68Ga has resulted in the emergence of studies evaluating its clinical role in cancer imaging. Preliminary findings have demonstrated that, in contrast to radiotracers taking advantage of cancer-specific targets such as PSMA and DOTATATE, FAPs as a target are the most promising that can compete with 18FDG in terms of widespread indications. They also have the potential to overcome the shortcomings of 18FDG, particularly false-positive uptake due to inflammatory or infectious processes, low sensitivity in certain cancer types, and radiotherapy planning. In addition, the attractive theranostic properties may facilitate the treatment of many refractory cancers. This review summarizes the current FAP variants and related clinical studies, focusing on radiopharmacy, dosimetry, and diagnostic and theranostic applications.Serkan KuyumcuYasemin SanliRathan M. SubramaniamRathan M. SubramaniamFrontiers Media S.A.articlePETcancer-associated fibroblastfibroblast activation proteintheranostic68Ga-FAPI04FAPINeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENFrontiers in Oncology, Vol 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	PET cancer-associated fibroblast fibroblast activation protein theranostic 68Ga-FAPI04 FAPI Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	PET cancer-associated fibroblast fibroblast activation protein theranostic 68Ga-FAPI04 FAPI Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Serkan Kuyumcu Yasemin Sanli Rathan M. Subramaniam Rathan M. Subramaniam Fibroblast-Activated Protein Inhibitor PET/CT: Cancer Diagnosis and Management
description	Fibroblast activation protein (FAP), overexpressed on cancer-associated fibroblasts (CAFs), is a novel target for molecular imaging of various tumors. Recently, the development of several small-molecule FAP inhibitors for radiolabeling with 68Ga has resulted in the emergence of studies evaluating its clinical role in cancer imaging. Preliminary findings have demonstrated that, in contrast to radiotracers taking advantage of cancer-specific targets such as PSMA and DOTATATE, FAPs as a target are the most promising that can compete with 18FDG in terms of widespread indications. They also have the potential to overcome the shortcomings of 18FDG, particularly false-positive uptake due to inflammatory or infectious processes, low sensitivity in certain cancer types, and radiotherapy planning. In addition, the attractive theranostic properties may facilitate the treatment of many refractory cancers. This review summarizes the current FAP variants and related clinical studies, focusing on radiopharmacy, dosimetry, and diagnostic and theranostic applications.
format	article
author	Serkan Kuyumcu Yasemin Sanli Rathan M. Subramaniam Rathan M. Subramaniam
author_facet	Serkan Kuyumcu Yasemin Sanli Rathan M. Subramaniam Rathan M. Subramaniam
author_sort	Serkan Kuyumcu
title	Fibroblast-Activated Protein Inhibitor PET/CT: Cancer Diagnosis and Management
title_short	Fibroblast-Activated Protein Inhibitor PET/CT: Cancer Diagnosis and Management
title_full	Fibroblast-Activated Protein Inhibitor PET/CT: Cancer Diagnosis and Management
title_fullStr	Fibroblast-Activated Protein Inhibitor PET/CT: Cancer Diagnosis and Management
title_full_unstemmed	Fibroblast-Activated Protein Inhibitor PET/CT: Cancer Diagnosis and Management
title_sort	fibroblast-activated protein inhibitor pet/ct: cancer diagnosis and management
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/f6b7392e8fb940db825892af269b3b9a
work_keys_str_mv	AT serkankuyumcu fibroblastactivatedproteininhibitorpetctcancerdiagnosisandmanagement AT yaseminsanli fibroblastactivatedproteininhibitorpetctcancerdiagnosisandmanagement AT rathanmsubramaniam fibroblastactivatedproteininhibitorpetctcancerdiagnosisandmanagement AT rathanmsubramaniam fibroblastactivatedproteininhibitorpetctcancerdiagnosisandmanagement
_version_	1718439365247500288

Fibroblast-Activated Protein Inhibitor PET/CT: Cancer Diagnosis and Management

Ejemplares similares